Dr. Hin Hin Ko, MD

Claim this profile

St. Paul's Hospital

Studies Primary Biliary Cirrhosis
Studies Autoimmune Hepatitis
3 reported clinical trials
3 drugs studied

Affiliated Hospitals

Image of trial facility.
St Paul's Hospital
Image of trial facility.
G.I. Research Institute

Clinical Trials Hin Hin Ko, MD is currently running

Image of trial facility.

EP-104IAR

for EoE

This trial tests a new drug, EP-104IAR, in adults with eosinophilic esophagitis (EoE). The drug is given during an endoscopy to see if it can reduce inflammation and symptoms in the esophagus.
Recruiting0 awards Phase 1 & 2
Image of trial facility.

Observational Study

for Autoimmune Hepatitis

CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome. This study creates a nationwide registry and network focusing on high quality long-term follow-up of individual patient data from major Canadian centers. Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) are rare and slowly progressive liver diseases associated with development of cirrhosis, liver cancer (HCC) and liver failure requiring liver transplantation or leading to premature death. The rarity and slowly progressive nature of these autoimmune liver diseases make them difficult to study and only a large scale approach combining patient data from multiple centers across Canada will allow new insights. The primary aim of the Canadian Network for Autoimmune Liver Disease is to build a Canadian registry of patients with PBC, AIH, and overlap syndrome. We capture patient characteristics, laboratory assessments and natural history, patient-reported outcomes including quality of life measures and environmental exposures, response to treatment, and pre- and post-transplant outcomes. We will then identify risk factors associated with critical outcomes for the patient, including response to treatment, progression to transplant, risk of liver cancer, and recurrent disease after transplant. We can identify biomarkers (biochemical indicators of progression of disease) to help diagnose autoimmune liver disease at its earliest stages, ensuring timely treatment and preventing disease progression. CaNAL will provide a better understanding of autoimmune liver diseases, biomarkers predictive of disease progression or non-response to therapy as well as better knowledge of the etiology and pathogenesis. CaNAL will also help to serve as a platform for conducting clinical trials or targeted lab-studies to answer important questions that are unlikely to be evaluated by the pharmaceutical industry.
Recruiting1 award N/A1 criteria

More about Hin Hin Ko, MD

Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Hin Hin Ko, MD has experience with
  • Observational
  • EP547
  • EP-104IAR

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Hin Hin Ko, MD specialize in?
Is Hin Hin Ko, MD currently recruiting for clinical trials?
Are there any treatments that Hin Hin Ko, MD has studied deeply?
What is the best way to schedule an appointment with Hin Hin Ko, MD?
What is the office address of Hin Hin Ko, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security